Study
| Phase II-III, multicenter, randomized, double-blind, placebo-controlled study (SEAL) |
| Advanced dedifferentiated liposarcoma who received 2-5 lines chemotherapy |
| Selinexor (N: 188) or placebo (N:97) twice weekly in 6-week cycles |
Efficacy
| No difference in OS |
| mPFS:2.8 vs 2.1 months, [HR:0.70 (0.52-0.95), p:0.011] |
Safety
| Treatment related death: 4 (2.1%) vs 3 (3.1%) |
| Grade >= 3 AEs with selinexor: Decreased appetite (7.5%), fatigue (6.4%), nausea (5.9%) |
J Clin Oncol. 2022 Apr 8;JCO2101829.
http://doi.org/10.1200/jco.21.01829
Reviewed by Hasan Cagri Yildirim, MD on May 20, 2022
